Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial

Acta Oncologica

Volumn 52, Issue 5, 2013, Pages 956-962

  Modest, Dominik P ^a   Laubender, Ruediger P ^a   Stintzing, Sebastian ^a   Giessen, Clemens ^a   Schulz, Christoph ^a   Haas, Michael ^a   Mansmann, Ulrich ^a   Heinemann, Volker ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; B RAF KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SURVIVAL TIME; TREATMENT RESPONSE; WILD TYPE; CANCER SURVIVAL; GENE MUTATION; LIVER METASTASIS; LYMPH NODE METASTASIS; PYROSEQUENCING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84877653304     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.752580     Document Type: Article

References (16)

1. Allegra CJ, J essup JM , S omerfi eld MR , H amilton SR , H ammond EH , Hayes DF , et al . American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy . J Clin Oncol 2009; 27: 2091-6 .
2. Jonker DJ , O 'Callaghan C J, K arapetis C S , Z alcberg J R , T u D , Au HJ , et al . Cetuximab for the treatment of colorectal cancer . N Engl J Med 2007; 357: 2040-8 .
3. Van Cutsem E, Köhne CH, Láng I , Folprecht G , Nowacki MP , Cascinu S , et al . Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011; 29: 2011-9 .
4. Bokemeyer C, B ondarenko I , H artmann JT , De Braud F , Schuch G , Zubel A , et al . Effi cacy according to biomarker status of cetuximab plus FOLFOX-4 as fi rst-line treatment for metastatic colorectal cancer: The OPUS study . Ann Oncol 2011; 22: 1535-46 .
5. Douillard JY , S iena S , C assidy J, Tabernero J, B urkes R , Barugel M , et al . Randomized, phase III trial of panitumumab with infusional fl uorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as fi rst-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study . J Clin Oncol 2010; 28: 4697-705 .
6. Van Cutsem E , P eeters M , S iena S , H umblet Y , H endlisz A , Neyns B , et al . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer . J Clin Oncol 2007; 25: 1658-64 .
7. Karapetis CS , K hambata-Ford S , J onker DJ , O 'Callaghan CJ , Tu D , Tebbutt NC , et al . K-ras mutations and benefi t from cetuximab in advanced colorectal cancer . N Engl J Med 2008; 359: 1757-65 .
8. Piessevaux H , v an Cutsem E , B okemeyer C , S chlichting M , Heeger S , Tejpar S . Early tumor shrinkage and clinical outcome in metastatic colorectal cancer: Analysis of predictive utility in the CRYSTAL and OPUS studies . JSMO, Osaka. 2012 July 28th .
9. Suzuki C , B lomqvist L , S undin A , J acobsson H , B ystr öm P , Berglund A , et al . The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy . Ann Oncol 2012; 23: 948-54 .
10. Maughan TS , A dams R A , S mith C G , M eade AM , Seymour MT , Wilson RH , et al . Addition of cetuximab to oxaliplatin-based fi rst-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial . Lancet 2011; 377: 2103-14 .
11. Anderson J R , C ain K C, G elber R D . Analysis of survival by tumor response . J Clin Oncol 1983; 1: 710-9 .
12. Neumann J, Z eindl-Eberhart E, K irchner T , J ung A . Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer . Pathol Res Pract 2009; 205: 858-62 .
13. Moosmann N , v on Weikersthal LF, V ehling-Kaiser U , Stauch M , Hass HG , Dietzfelbinger H , et al . Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as fi rst-line treatment for patients with metastatic colorectal cancer: AIO KRK 0104-A randomized trial of the German AIO CRC Study Group . J Clin Oncol 2011; 29: 1050-8 .
14. Modest DP , J ung A , M oosmann N , L aubender RP , Giessen C , Schulz C , et al . The infl uence of KRAS and BRAF mutations on the effi cacy of cetuximab-based fi rstline therapy of metastatic colorectal cancer: An analysis of the AIO KRK 0104 trial . Int J Cancer 2012; 131: 980-6 .
15. Piessevaux H , B uyse M , De Roock W , P renen H , Schlichting M , Van Cutsem E , et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) . Ann Oncol 2009; 20: 1375-82 .
16. Tejpar S , C elik I , S chlichting M , S artorius U , B okemeyer C, Van Cutsem E . Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with fi rst-line chemotherapy with or without cetuximab . J Clin Oncol 2012; 30: 3570-7 .